Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Clinical trial NCT07130032 · RECRUITING

Trial details

NCT number: NCT07130032
Sponsor: EuroCityClinic LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Cutaneous Melanoma

Start date: 2025-08-14
Primary completion: 2025-08-14
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.